Mereo BioPharma Group plc (MAH0) — Cash Flow-to-Debt Ratio
Mereo BioPharma Group plc (MAH0) has a Cash Flow-to-Debt Ratio of -1.54x as of December 2025, meaning its operating cash flow of €-7.68 Million could theoretically repay -2% of its total liabilities (€5.00 Million) in one year. See Mereo BioPharma Group plc free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Mereo BioPharma Group plc Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Mereo BioPharma Group plc across 10 annual periods. Also explore how fast is Mereo BioPharma Group plc growing its equity to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Mereo BioPharma Group plc (2016–2025)
Year-by-year debt coverage analysis for Mereo BioPharma Group plc. For market capitalisation and broader financial context, see MAH0 market cap overview.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -6.19x | €-30.97 Million | €5.00 Million | ▼ -190.9% |
| 2024 | -2.13x | €-32.83 Million | €15.42 Million | ▼ -60.8% |
| 2023 | -1.32x | €-21.13 Million | €15.96 Million | ▲ +10.6% |
| 2022 | -1.48x | €-38.82 Million | €26.21 Million | ▼ -986.0% |
| 2021 | -0.14x | €-5.24 Million | €38.41 Million | ▲ +62.5% |
| 2020 | -0.36x | €-28.34 Million | €77.92 Million | ▲ +63.4% |
| 2019 | -0.99x | €-45.93 Million | €46.19 Million | ▼ -48.3% |
| 2018 | -0.67x | €-23.14 Million | €34.51 Million | ▲ +29.4% |
| 2017 | -0.95x | €-32.15 Million | €33.85 Million | ▲ +76.0% |
| 2016 | -3.95x | €-29.66 Million | €7.51 Million | — |